Central venous catheter capable of preventing thrombus

Abstract

The invention discloses a central venous catheter capable of preventing thrombus. The central venous catheter comprises a central venous catheter body and medical coating layers coating the walls of the catheter. Each medicine coating layer comprises medicine and a medicine carrier, wherein the medicine is tissue factor pathway inhibitor TFPI-1 or TFPI-2, and the mass ratio of the medicine to the medicine carrier is 1:(4-7.9). Both the inner wall and the outer wall of the catheter body are coated with the medicine coating layers. The thickness of the medicine coating layers is 20-40 micrometers. The central venous catheter has the advantages that the tissue factor pathway inhibitor is applied to the central venous catheter body, so that thrombogenesis and bacterial infection in the central venous catheter body are effectively prevented, the pain and burden of a patient are reduced, the workload of medical staff is reduced, and working efficiency is improved. The tissue factor pathway inhibitor is tissue factor physiological inhibitor, has good blood compatibility and tissue compatibility compared with other medicine, has no toxic or side effect and has few influences on the human body.

Description

Technical field [0001] The invention relates to a medical venous catheter, in particular to a central venous catheter that can prevent thrombosis. Background technique [0002] The central venous catheter is a common medical device, which is inserted into a patient's vein, such as the internal jugular vein, through a puncture technique, for infusion of the patient. Many patients with poor peripheral vascular conditions require indwelling central venous catheters as an intravenous infusion channel. Due to its advantages of less pain and long indwelling time, it has been popularized clinically, but a series of complications will occur after catheterization, especially catheter-related Sexual thrombosis not only adds pain and economic burden to patients, but also brings difficulties to medical staff. Once the thrombosis falls off, it will cause pulmonary embolism and even life-threatening. [0003] At present, the main clinical method to prevent thromboembolism is to seal the tube w...

AI Technical Summary

Problems solved by technology

The clinical treatment of thromboembolism and catheter blockage caused by fibrin sheath wrapping is generally to repeatedly use urokinase for thrombolysis after the protein sheath is formed, but the effect is not good

Repeated urokinase thrombolysis also has the following disadvantages: 1. The cost is expensive, and the patient cannot afford it. 2. Urokinase has complications of systemic hemorrhage, and the life-threatening complications are cerebral hemorrhage complications.

The second is to use the fibrin sheath avulsion technique to pull out the fibrin sheath, but this operation is difficult, and it is not easy to carry out in general hospitals, and the operation needs to be performed under contrast, which is expensive

Images